Clinical trial · Interventional
Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor
Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bladder cancer is a common urological malignant disease. Patients with bladder cancer will first be managed with transurethral resection (TUR) of bladder tumor. For many years, monopolar transurethral resection of bladder tumor (TURP) has been the gold standard for treatment. However, complications including bleeding, bladder perforation and inadequate sampling of deep tumor biopsy remain the major concerns. Recently published papers suggested that the newer bipolar TUR technology has similar surgical outcomes but less complications comparing with monopolar TUR. In this study, investigators will investigate the benefit of new technology as compared with conventional monopolar resection on tumor clearance, complication and recurrence rates.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urinary Bladder Tumor | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bipolar diathermy | Device | — | UNRESOLVED |
| Monopolar diathermy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Monopolar TUR
- description
- Monopolar diathermy is used to perform tranurethral resection of bladder tumor
- interventionNames
- Device: Monopolar diathermy
- type
- EXPERIMENTAL
- label
- Biploar TUR
- description
- Bipolar diathermy is used to perform transurethral resection of bladder tumor
- interventionNames
- Device: Bipolar diathermy
Primary outcomes (2)
- measure
- Muscle sampling rate
- timeFrame
- An expected average of 7 days post operation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult male or female patients (age ≥ 18) * Patients who have diagnosed with bladder cancer (either primary or recurrent) by cystoscopy Exclusion Criteria: * Patients who are scheduled for second TUR within 6 weeks after the previous TUR
References
Publications (0)
Data not yet available